Kommentar
Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes
JAMA · 04.08.2026 · 336 (5) · 374
DOI: 10.1001/jama.2026.10443 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA, erschienen am 04.08.2026. Verfasst von Kishore M Gadde und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of Surgery, University of California Irvine School of Medicine, Orange. Die Arbeit nennt 15 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Gastrointestinal Surgery, Department of Surgery, University of California Irvine School of Medicine, Orange.
- Division of Gastroenterology, Department of Medicine, University of California Irvine School of Medicine, Orange.
- Pennington Biomedical Research Center, Baton Rouge, Louisiana.
Zitieren
APA
Gadde, K. M., Talebloo, J., & Heymsfield, S. B. (2026). Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes. JAMA, 336(5), 374. https://doi.org/10.1001/jama.2026.10443
Vancouver
Gadde KM, Talebloo J, Heymsfield SB. Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes. JAMA. 2026;336(5):374. doi:10.1001/jama.2026.10443
BibTeX
@article{Gadde2026,
author = {Gadde, Kishore M and Talebloo, Jonanne and Heymsfield, Steven B},
title = {Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes},
journal = {JAMA},
year = {2026},
volume = {336},
number = {5},
pages = {374},
doi = {10.1001/jama.2026.10443}
}
EUVIMED